WebMay 18, 2024 · By Florian Wittlinger. Objects in collection. UK AE AR AT AU BE BO BR CA CH CL CN CO CR DE DK ... WebFlorian Wittlinger Activities. Collapse all. expand_more. Employment (1) sort Sort. Eberhard Karls Universität Tübingen: Tübingen, Baden-Württemberg, DE (Institute for …
Design of a “Two-in-One” Mutant-Selective Epidermal Growth …
WebFlorian Wittlinger 1 , Stefan A Laufer 1 Affiliation 1 Tuebingen Center for Academic Drug Discovery & Development, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen, Germany. PMID: 34053372 DOI: 10.1080/17460441.2024. ... WebOct 21, 2024 · Florian Wittlinger 1 , David E Heppner 2 , Ciric To 3 , Marcel Günther 1 , Bo Hee Shin 3 , Jaimin K Rana 2 , Anna M Schmoker 2 , Tyler S Beyett 2 , Lena M Berger 4 5 , Benedict-Tilman Berger 4 5 , Nicolas Bauer 4 5 , James D Vasta 6 , Cesear R Corona 6 , Matthew B Robers 6 , Stefan Knapp 4 5 , Pasi A Jänne 3 7 , Michael J Eck 2 , Stefan A ... marian medical centre pala
The pre-clinical discovery and development of osimertinib used ... - PubMed
WebAug 17, 2024 · “Good science is never done in isolation. Many thanks to all members of our lab and collaborators for their effort and support these past years.Image: Surbhi Chitnis … WebOct 20, 2024 · Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase domain. Drug resistance due to treatment-acquired mutations has motivated the development of successive generations of inhibitors that … WebFeb 11, 2024 · Florian Wittlinger Michael J Eck Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer is a persistent challenge in cancer therapy. marian medical center patient portal